New perspective for nutritional support of cancer patients: Enteral/parenteral nutrition

Akbulut, Gamze

doi:10.3892/etm.2011.247

Cited by 30 publications

(39 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a significant association between surgical cancer treatment and the development of sarcopenia was not observed in the present study. Chemotherapy may also reduce the tumor burden, but the therapeutic effect is accompanied by severe cytotoxicity, causing symptoms that include vomiting and mucosal damage, which increase the body's nutritional requirements (25,26). The data obtained from the current study demonstrated that the incidence of sarcopenia in patients receiving chemotherapy was slightly lower than that in patients receiving other treatments, but the difference was not significant.…”

Section: Discussionmentioning

confidence: 49%

Incidence and risk factor analysis for sarcopenia in patients with cancer

Zhang

Sui

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 49%

Incidence and risk factor analysis for sarcopenia in patients with cancer

Zhang

Sui

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

“…Oral GLN may reduce the duration and severity of mucositis, 9,12,19,22,23 with fewer days on opiods. 22,23 The exact mechanism by which oral GLN prevents mucositis is not clear.…”

mentioning

confidence: 99%

“…22,23 The exact mechanism by which oral GLN prevents mucositis is not clear. 9 Van Zyl's systematic review 20 on oral GLN provided new evidence of a significant reduction (p = 0.03) in > grade 2 mucositis with a relative risk reduction of 24%.…”

mentioning

confidence: 99%

“…9 Van Zyl's systematic review 20 on oral GLN provided new evidence of a significant reduction (p = 0.03) in > grade 2 mucositis with a relative risk reduction of 24%. Trends for less days of opiate use with mucositis 22 were seen in autologous (p < 0.01), but not allogeneic, bone marrow transplant (BMT) patients. 19 Oral GLN may reduce graft-versus-host disease (GVHD).…”

mentioning

confidence: 99%

“…19 Oral GLN may reduce graft-versus-host disease (GVHD). 22,23 It may decrease the severity and duration of stomatitis in children and adults after chemotherapy, as well as in head and neck cancer patients. 12 Oral GLN may also prevent or delay the occurrence of radiationinduced oesophagitis among cancer patients treated by radiotherapy to the thoracic area with or without chemotherapy.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Glutamine and its use in selected oncology settings

Tydeman-Edwards

2017

South African Journal of Clinical Nutrition

View full text Add to dashboard Cite

This review summarises the latest evidence for the use of glutamine (GLN) in oncology taking cognisance of current systematic reviews and available guidelines. Various studies in adults suggest that GLN supplementation suppresses tumour growth, by restoring the function of natural killer cells; improves protein metabolism; and, possibly enhances the effect of cancer therapy. There is insufficient data on whether GLN supplementation reduces the incidence of infection, although a trend exists towards such a reduction. GLN-supplemented enteral nutrition was superior in improving immune function, whilst oral GLN alone appeared to have no effect on: mortality; infections; time to neutrophil recovery; or, relapse. GLN significantly reduces the duration of diarrhoea, but had no effect on its prevention. Oral GLN may reduce the duration and severity of mucositis, with fewer days on opioid therapy. Oral GLN, but not intravenous GLN (IV-GLN), may decrease mucositis and graft-versus-host disease in adult bone marrow transplant patients. Currently, the evidence for reduction of severe mucositis or infection rate in children is not statistically significant, but GLN does significantly reduce parenteral nutrition use, reflecting a possible improvement in lower gut mucositis. Nevertheless, too few studies exist to either support or refute that GLN supplementation either reduces the duration of, or prevents the progression to, severe mucositis. In children, there is no significant evidence that IV-GLN supplementation reduces infection rates, hospital length of stay (LOS), graft-versus-host disease, or mortality. Children with solid tumours on chemotherapy receiving oral GLN supplementation showed significant improvements in some nutritional and immunological parameters, as well as the severity of stomatitis and need for antibiotic therapy. Caution is recommended when considering provision of IV-GLN to oncology patients who have hepatic or renal insufficiency or failure. Monitoring of hepatic and renal function is recommended. Further studies are needed specifically on the use of glutamine in an oncology setting. Larger, multicentre, randomised placebo-controlled studies are needed in both adult and paediatric oncology populations.

show abstract

Nutritional Management of Oncologic Diseases

Mauldin

2023

Applied Veterinary Clinical Nutrition

View full text Add to dashboard Cite

New perspective for nutritional support of cancer patients: Enteral/parenteral nutrition

Cited by 30 publications

References 72 publications

Incidence and risk factor analysis for sarcopenia in patients with cancer

Incidence and risk factor analysis for sarcopenia in patients with cancer

Glutamine and its use in selected oncology settings

Nutritional Management of Oncologic Diseases

Contact Info

Product

Resources

About